Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Tofacitinib is an effective and safe treatment for alopecia areata.

Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.

Adults with alopecia areata stick to their medication better than those with atopic dermatitis.

Baricitinib significantly regrows hair in severe alopecia areata patients.

The AAcQLI is a promising tool for assessing quality of life in children with alopecia areata.

New tools help doctors better assess and treat alopecia areata in kids by considering more than just hair loss.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.

DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.

Disease-specific tools better assess quality of life in alopecia areata patients.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Polygenic Score can help predict severe psoriasis and psoriatic arthritis.

The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.

Higher IL-21 levels may help predict alopecia areata activity.

Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Significant hair regrowth doesn't always mean complete hair recovery in alopecia areata.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

UDCA reduces inflammation and joint damage in rheumatoid arthritis.

Skin and mucous symptoms are key for diagnosing autoimmune connective tissue diseases.

Alopecia areata affects quality of life more in adolescents than adults.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.